- Home
- DVAX vs XNCR Comparison
DVAX vs XNCR Comparison
Compare DVAX & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- XNCR
- Stock Information
- Founded
- DVAX 1996
- XNCR 1997
- Country
- DVAX United States
- XNCR United States
- Employees
- DVAX N/A
- XNCR N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- DVAX Health Care
- XNCR Health Care
- Exchange
- DVAX Nasdaq
- XNCR Nasdaq
- Market Cap
- DVAX 1.3B
- XNCR 547.8M
- IPO Year
- DVAX 2004
- XNCR 2013
- Fundamental
- Price
- DVAX $9.41
- XNCR $8.60
- Analyst Decision
- DVAX Buy
- XNCR Buy
- Analyst Count
- DVAX 4
- XNCR 10
- Target Price
- DVAX $26.50
- XNCR $23.33
- AVG Volume (30 Days)
- DVAX 1.9M
- XNCR 734.4K
- Earning Date
- DVAX 11-06-2025
- XNCR 11-05-2025
- Dividend Yield
- DVAX N/A
- XNCR N/A
- EPS Growth
- DVAX N/A
- XNCR N/A
- EPS
- DVAX N/A
- XNCR N/A
- Revenue
- DVAX $316,268,000.00
- XNCR $146,929,000.00
- Revenue This Year
- DVAX $23.23
- XNCR $22.06
- Revenue Next Year
- DVAX $16.57
- XNCR N/A
- P/E Ratio
- DVAX N/A
- XNCR N/A
- Revenue Growth
- DVAX 26.66
- XNCR N/A
- 52 Week Low
- DVAX $9.22
- XNCR $6.92
- 52 Week High
- DVAX $14.63
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- DVAX 33.66
- XNCR 57.89
- Support Level
- DVAX $9.51
- XNCR $8.25
- Resistance Level
- DVAX $9.94
- XNCR $8.73
- Average True Range (ATR)
- DVAX 0.29
- XNCR 0.38
- MACD
- DVAX -0.07
- XNCR 0.07
- Stochastic Oscillator
- DVAX 0.85
- XNCR 78.76
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.